Trevi Therapeutics

TRVI

Market cap $1.36B

11.10 USD

+0.46

4.32%

At close Updated Feb 23, 4:00 PM EST

Pre-market

After hours

11.44

+0.34

3.06%

1 day

4.32%

5 days

6.42%

1 month

11.11%

3 months

-2.72%

6 months

52.47%

Year to date

-6.64%

1 year

157.54%

5 years

292.23%

10 years

40.68%

About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Employees: 34

Healthcare Biotechnology